Skip to Content
Søk Menu

Real World Longer-Term Follow-Up Data Confirms the Effectiveness and Safety of Avelumab 1st Line Maintenance Treatment of Low-Burden Urothelial Cancer

Results from the AVENANCE trial suggest that avelumab may provide a promising maintenance treatment option for patients with low-burden urothelial carcinoma, showing encouraging survival and progression-free survival outcomes after chemotherapy.
Philippe Barthélémy

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Nyrekreft
Thomas Powles

Bladder Cancer Treatment Advancements: Key Findings and Progress

/ Thomas Powles
ASCOGU25Blærekreft Play the Video 08:59

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostatakreft

Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma

/ Deniz Tural / Jan Andreasen
ASCOGU25Blærekreft

Efficacy of 1L Treatment Does Not Predict Efficacy of 2L Cabozantinib for Patients with mRCC

/ Martin Zarba / Jan Andreasen
ASCOGU25Nyrekreft

Danish Study Reveals Doubling of Kidney Cancer Cases and a Growing Gender Gap 

/ Johanne Ahrenfeldt / Jan Andreasen
ASCOGU25Nyrekreft
Petros Grivas

Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus

/ Petros Grivas
ASCOGU25BlærekreftType 2-diabetes Play the Video 02:42
Peter J. Goebell

Real-World Effectiveness of Avelumab in First-Line Maintenance for Bladder Cancer

/ Peter J. Goebell
ASCOGU25Blærekreft Play the Video 06:12
Nick James

Oestrogen Reimagined: A Breakthrough Approach for Metastatic Prostate Cancer

/ Nick James
ASCOGU25Prostatakreft Play the Video 09:06
Back to top